

ORN R-2336

Order no. 130-104-431 Order no. 130-104-432

RNA motifs have been described activating either TLR7 or TLR8 only or both, TLR7 and TLR8, simultaneously. TLR7 and TLR8 are expressed on human cells with a distinct expression pattern. In human cells, pDCs and B cells express predominantly TLR7 whereas TLR8 is mainly expressed on cells of the myeloid lineage, such as monocytes, macrophages, and myeloid dendritic cells (mDCs). In mice, TLR7 is also expressed on mDCs and monocytes whereas murine TLR8 is functionally impaired.^{1,7}

Due to the sensitive nature of RNA, most nucleic acid TLR7/8 agonists need to be formulated with cationic lipids in order to activate an appropiate immune response. The recommended cationic lipid is DOTAP-Cl (1,2-Dioleoyloxy-3-trimethylammonium-propane chloride).

3. Applications

3.1 General application

• TLR7 and TLR8 agonists can be used for the activation of immune cells, such as human PBMCs, murine splenocytes, or isolated immune cells, e.g., B cells, pDCs, mDCs, and monocytes.

3.2 Specific applications

• ORN R-2336⁶ activates specifically human and murine TLR7 and induces a TLR7-biased spectrum of cytokines from human PBMCs (predominantly IFN-a).

4. Instructions for use

4.1 Recommended concentrations

Recommended concentrations for use are

for human and murine immune cells: 0.05–2 μM

▲ An excessively high concentration of ORNs may result in decreased activity. Therefore, the optimal concentration range should be determined for individual assay systems.

4.2 Reconstitution protocol

- 1. Spin down pellet.
- a) For 200 μg lyophilized ORN: To obtain a 200 μM solution resuspend pellet in 132 μL of RNase-free Water.
 - b) For 1 mg lyophilized ORN:
 To obtain a 200 μM solution resuspend pellet in 661 μL of RNase-free Water.
- 3. Vortex and incubate overnight at 4 °C.
- 4. Store aliquots at -20 °C.

Contents

- 1. Description
- 2. Background information
- 3. Applications
 - 3.1 General application
 - 3.2 Specific applications
- 4. Instructions for use
 - 4.1 Recommended concentrations
 - 4.2 Reconstitution protocol
 - 4.3 Recommended formulation protocol
- 5. References

1. Description

Components	130-104-431: 200 μg lyophilized ORN 1 mL RNase-free Water
	400 µL DOTAP-Chloride (1 mg/mL)
	or 130-104-432: 1 mg lyophilized ORN 1 mL RNase-free Water 5×400 µL DOTAP-Chloride (1 mg/mL)
Description	TLR7 agonist.
Product format	Lyophilized ORN without carrier protein or preservatives.
Sequence	rG-rA-rC-rA-rC-rA-rC-rA-rC-rA-rC-rU-rC- rA-rC-rA-rC-rA-rC-rA-rC-rA-rC-rA * Phosphodiester backbone
Endotoxin level	Low endotoxin (<1 EU/mg) as determined by kinetic Limulus Amebocyte Lysate (LAL) assay.
Storage	Store lyophilized product at -20 °C. Upon reconstitution, aliquots should be stored at -20 °C and are stable for 6 months. Avoid repeated freeze-thaw cycles. Store DOTAP-Cl at $2-8$ °C. The expiration date is indicated on the vial label.

2. Background information

TLR7 and TLR8 are members of the Toll-like-receptor (TLR) family recognizing pathogen-associated molecular patterns.^{1,7} TLR7 and 8 recognize (virally derived) double- or single-stranded RNA leading to activation of immune cells. These natural ligands can be mimicked by short synthetic RNAs (oligoribonucleotides; ORNs).²⁻⁵

Miltenyi Biotec B.V. & Co. KG

Phone +49 2204 8306-0, Fax +49 2204 85197 macsde@miltenyi.com

www.miltenyibiotec.com

140-004-544.02

Friedrich-Ebert-Straße 68, 51429 Bergisch Gladbach, Germany

4.3 Recommended formulation protocol

For formulation of the ORNs with DOTAP-Cl we recommend to use a ratio of 2 μ M ORN and 25 μ g/mL DOTAP-Cl. The complexation of ORN with DOTAP-Cl should be performed in water, PBS or serumfree medium in a smaller volume (e.g., 1/10 of well volume). Always add DOTAP-Cl to the ORN solution. We recommend to keep this ratio constant if probing several ORN concentrations. For dilution series, ORN can be formulated at an initial concentration of 2 μ M ORN and 25 μ g/mL DOTAP-Cl. This complex can be diluted with medium or water to the desired concentrations.

Final concentration per well	Water	ORN (200 μM)	DOTAP-Cl (1 mg/mL)
2 μM ORN	8 µL	2 μL	
25 μg/mL DOTAP-Cl	5 μL		5 μL

Add 10 μ L of diluted DOTAP-Cl to 10 μ L of diluted ORN solution, mix by pipetting, and add to cells. Alternatively, further dilute solution to the desired concentration.

Example:

	per 96-well round bottom plate
Recommended cell density (for PBMCs)	1×10 ⁶ cells/well
Cell culture medium	180 μL
ORN/DOTAP-Cl complex	20 µL
Total volume	200 µL

5. References

- Blasius, A. L., and Beutler, B. (2010) Intracellular toll-like receptors. Immunity 32(3): 305–315.
- Diebold, S. S. et al. (2004) Innate antiviral responses by means of TLR7mediated recognition of single-stranded RNA. Science 303: 1529–1531.
- Forsbach, A. *et al.* (2008) Identification of RNA sequence motifs stimulating sequence-specific TLR8-dependent immune responses. J. Immunol. 180: 3729– 3738.
- Forsbach, A. *et al.* (2011) Dual or triple activation of TLR7, TLR8, and/or TLR9 by single-stranded oligoribonucleotides. Nucleic Acid Ther. 21(6): 423–436.
- Heil, F. *et al.* (2004) Species-specific recognition of single-stranded RNA via toll-like receptor 7 and 8. Science 303: 1526–1529.
- Jurk, M. *et al.* (2011) Immunostimulatory potential of silencing RNAs can be mediated by a non-uridine-rich toll-like receptor 7 motif. Nucleic Acid Ther. 21(3): 201–214.
- Kawai, T., and Akira, S. (2010) The role of pattern-recognition receptors in innate immunity: update on Toll-like receptors. Nat. Immunol. 11(5): 373–384.

Refer to www.miltenyibiotec.com for all data sheets and protocols. Miltenyi Biotec provides technical support worldwide. Visit www.miltenyibiotec.com/local to find your nearest Miltenyi Biotec contact.

Legal notices

Limited product warranty

Miltenyi Biotec B.V. & Co. KG and/or its affiliate(s) warrant this product to be free from material defects in workmanship and materials and to conform substantially with Miltenyi Biotec's published specifications for the product at the time of order, under normal use and conditions in accordance with its applicable documentation, for a period beginning on the date of delivery of the product by Miltenyi Biotec or its authorized distributor and ending on the expiration date of the product's applicable shelf life stated on the product label, packaging or documentation (as applicable) or, in the absence thereof, ONE (1) YEAR from date of delivery ("Product Warranty"). Miltenyi Biotec's Product Warranty is provided subject to the warranty terms as set forth in Miltenyi Biotec's General Terms and Conditions for the Sale of Products and Services available on Miltenyi Biotec's website at www.miltenyibiotec.com, as in effect at the time of order ("Product Warranty"). Additional terms may apply. BY USE OF THIS PRODUCT, THE CUSTOMER AGREES TO BE BOUND BY THESE TERMS. THE CUSTOMER IS SOLELY RESPONSIBLE FOR DETERMINING IF A PRODUCT IS SUITABLE FOR CUSTOMER'S PARTICULAR PURPOSE AND APPLICATION METHODS.

Technical information

The technical information, data, protocols, and other statements provided by Miltenyi Biotec in this document are based on information, tests, or experience which Miltenyi Biotec believes to be reliable, but the accuracy or completeness of such information is not guaranteed. Such technical information and data are intended for persons with knowledge and technical skills sufficient to assess and apply their own informed judgment to the information. Miltenyi Biotec shall not be liable for any technical or editorial errors or omissions contained herein.

All information and specifications are subject to change without prior notice. Please contact Miltenyi Biotec Technical Support or visit www.miltenyibiotec.com for the most up-to-date information on Miltenyi Biotec products.

Licenses

This product and/or its use may be covered by one or more pending or issued patents and/or may have certain limitations. Certain uses may be excluded by separate terms and conditions. Please contact your local Miltenyi Biotec representative or visit Miltenyi Biotec's website at www.miltenyibiotec.com for more information.

The purchase of this product conveys to the customer the non-transferable right to use the purchased amount of the product in research conducted by the customer (whether the customer is an academic or for-profit entity). This product may not be further sold. Additional terms and conditions (including the terms of a Limited Use Label License) may apply.

CUSTOMER'S USE OF THIS PRODUCT MAY REQUIRE ADDITIONAL LICENSES DEPENDING ON THE SPECIFIC APPLICATION. THE CUSTOMER IS SOLELY RESPONSIBLE FOR DETERMINING FOR ITSELF WHETHER IT HAS ALL APPROPRIATE LICENSES IN PLACE. Miltenyi Biotec provides no warranty that customer's use of this product does not and will not infringe intellectual property rights owned by a third party. BY USE OF THIS PRODUCT, THE CUSTOMER AGREES TO BE BOUND BY THESE TERMS.

Trademarks

The Miltenyi Biotec logo is a registered trademark or trademark of Miltenyi Biotec and/or its affiliates in various countries worldwide.

Copyright © 2020 Miltenyi Biotec and/or its affiliates. All rights reserved.